1. Home
  2. NRDY vs GLSI Comparison

NRDY vs GLSI Comparison

Compare NRDY & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nerdy Inc.

NRDY

Nerdy Inc.

HOLD

Current Price

$0.92

Market Cap

127.9M

Sector

Technology

ML Signal

HOLD

Logo Greenwich LifeSciences Inc.

GLSI

Greenwich LifeSciences Inc.

HOLD

Current Price

$26.74

Market Cap

372.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NRDY
GLSI
Founded
2007
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
127.9M
372.0M
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
NRDY
GLSI
Price
$0.92
$26.74
Analyst Decision
Hold
Strong Buy
Analyst Count
1
1
Target Price
$1.00
$50.00
AVG Volume (30 Days)
846.1K
130.3K
Earning Date
05-29-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
13.16
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$6.08
N/A
Revenue Next Year
$8.52
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.77
$7.78
52 Week High
$1.90
$34.10

Technical Indicators

Market Signals
Indicator
NRDY
GLSI
Relative Strength Index (RSI) 45.05 52.78
Support Level $0.91 $21.43
Resistance Level $1.00 $29.91
Average True Range (ATR) 0.06 2.17
MACD 0.00 -0.03
Stochastic Oscillator 49.56 65.57

Price Performance

Historical Comparison
NRDY
GLSI

About NRDY Nerdy Inc.

Nerdy Inc is a curated direct-to-consumer platform for live online learning. Its proprietary platform leverages technology, including artificial intelligence ("AI"), to connect students, users, parents, guardians, and purchasers of all ages to tutors, instructors, subject matter experts, educators, and other professionals. The company provides learning experiences across numerous subjects and multiple formats, including one-on-one instruction, small group tutoring, large format classes, tutor chat, essay review, adaptive assessments, and self-study tools. The company generates revenue by selling services to learners and institutions for one-on-one instruction and small group tutoring.

About GLSI Greenwich LifeSciences Inc.

Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.

Share on Social Networks: